このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

中国における PNH に関する現実世界の多施設共同前向き観察研究 (ReWoPNH)

2026年9月22日 更新者:AstraZeneca

中国における発作性夜間ヘモグロビン尿症(PNH)に関する現実世界の多施設共同前向き観察研究

As a rare disease listed in the First Catalogue of Rare Diseases in China (National Health Commission of the People's Republic of China, 2019), PNH is poorly studied in China subse-quently leading to the inadequate elucidation of disease characteristics and clinical outcomes. Eculizumab was recently approved by NMPA. The availability of Eculizumab in China pro-vides people living with PNH with a new treatment option that can reduce disease symptoms and prevent the dysregulated complement system from causing further damage. A Phase Ⅳ study is necessary to understand the natural history of disease and the clinical outcomes with different medical interventions.

調査の概要

状態

完了

条件

詳細な説明

Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare and life-threatening acquired disorder of the pluripotent hematopoietic stem cell and therefore can affect erythrocytes, leukocytes, thrombocytes and probably some endothelial cells. These hematopoietic stem cells have acquired a somatic mutation in the phosphatidylinositol glycan class A (PIG-A) This gene is required for the synthesis of the glycosyl phosphatidyl-inositol (GPI) anchor, which is necessary to attach some proteins to the blood cell membrane. Therefore, a lack of two important complement regulatory proteins is observed on the cell surface: 'decay-accelerating factor' (DAF), also called 'CD55' and 'membrane inhibitor of reactive lysis' (MIRL), also called 'CD59' Thus, red blood cells are more vulnerable to the attack by the complement activation product MAC (complement membrane attack complex). This leads to a complement-mediated intravascular hemolysis. The predisposition of venous thrombosis, hemolytic anemia, complete thrombocytopenia, and thrombosis are the three main characteristics of the disease. Its incidence is not really known but estimated at 0.1~0.6/100 000 per-sons/yr, and prevalence is estimated at 1~4 cases/100,000 persons/yr. PNH was listed in the First Catalogue of Rare Diseases in China, and its incidence was previously reported to be 1/100,000 persons/year, peak onset age 20~40 years.

PNH can be classified into 3 different forms: classical PNH, PNH associated with aplastic anemia (PNH-AA), and subclinical PNH, based on clinical features, bone marrow characteristics, and the size of the mutant clone. The traditional treatment of PNH is still aimed at "protecting" the PNH clone, reducing complement attack and destruction, and alleviating hemolysis with symptomatic supportive therapy. In acute hemolytic episodes, could be administered adrenal glucocorticoids, complemented by cell membrane stabilizers, folic acid, and alkaline drugs. In case of PNH-AA syndrome, treatment with androgens and immunosuppressants may be used; anticoagulation and heparin therapy should be given for the occurrence of thrombosis; other symptomatic supportive treatments include transfusion of red blood cells and platelets if necessary as well as antibacterial drugs in case of infection. Bone marrow transplantation is the only curative therapy for PNH presupposes, but patient need to achieve complete remission with chemotherapy first and a suitable donor is needed.

Besides supportive care, global guidance/consensus also recommend C5 complement inhibitor Eculizumab as a treatment method, and its use could significantly improve 5-year survival rate to 95.5%. Eculizumabis a humanized, first-in-class, anti-C5 antibody that binds with high affinity to C5 and blocks the terminal complement-C5a and C5b-9 formation, reducing the chronic uncontrolled complement activation and its consequences. Eculizumab has been approved for PNH by National Medical Products Administration in August, 2022.

研究の種類

観察的

入学 (実際)

724

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Hangzhou、中国
        • Research Site
    • Anhui
      • Hefei、Anhui、中国、230002
        • Research Site
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100000
        • Research Site
      • Beijing、Beijing Municipality、中国、100044
        • Research Site
    • Guangdong
      • Guangzhou、Guangdong、中国、510080
        • Research Site
      • Guangzhou、Guangdong、中国、510180
        • Research Site
      • Guangzhou、Guangdong、中国、510515
        • Research Site
    • Guangxi
      • Nanning、Guangxi、中国、530021
        • Research Site
    • Guizhou
      • Guiyang、Guizhou、中国、550004
        • Research Site
    • Hebei
      • Shijiazhuang、Hebei、中国、050000
        • Research Site
    • Heilongjiang
      • Harbin、Heilongjiang、中国、150001
        • Research Site
    • Henan
      • Zhengzhou、Henan、中国、450003
        • Research Site
      • Zhengzhou、Henan、中国、450052
        • Research Site
      • Zhengzhou、Henan、中国、463599
        • Research Site
    • Hubei
      • Wuhan、Hubei、中国、430030
        • Research Site
      • Wuhan、Hubei、中国、430000
        • Research Site
    • Hunan
      • Changsha、Hunan、中国、410008
        • Research Site
      • Changsha、Hunan、中国、410005
        • Research Site
    • Jiangsu
      • Nanjing、Jiangsu、中国、210029
        • Research Site
      • Nantong、Jiangsu、中国、226001
        • Research Site
      • Xuzhou、Jiangsu、中国、221002
        • Research Site
    • Jiangxi
      • Nanchang、Jiangxi、中国、330006
        • Research Site
      • Nanchang、Jiangxi、中国、330008
        • Research Site
    • Jilin
      • Changchun、Jilin、中国、130021
        • Research Site
    • Liaoning
      • Shenyang、Liaoning、中国、110001
        • Research Site
    • Shandong
      • Jinan、Shandong、中国、250000
        • Research Site
      • Qingdao、Shandong、中国、266000
        • Research Site
      • Zibo、Shandong、中国、255090
        • Research Site
    • Shangdong
      • Linyi、Shangdong、中国、276034
        • Research Site
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200040
        • Research Site
      • Shanghai、Shanghai Municipality、中国、200336
        • Research Site
    • Shanxi
      • Taiyuan、Shanxi、中国、030000
        • Research Site
      • Xi’an、Shanxi、中国、710061
        • Research Site
      • Xi’an、Shanxi、中国、710068
        • Research Site
    • Sichuan
      • Chengdu、Sichuan、中国、610041
        • Research Site
      • Chengdu、Sichuan、中国、610072
        • Research Site
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国、300020
        • Research Site
      • Tianjin、Tianjin Municipality、中国、300052
        • Research Site
      • Tianjin、Tianjin Municipality、中国、300190
        • Research Site
    • Yunnan
      • Kunming、Yunnan、中国、650034
        • Research Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Study Population:

Number of patients (estimate): 1000; Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

説明

Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Hemolysis:Concentration of LDH changes at each visit from base-line, of all patients
時間枠:12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with thrombosis within follow-up
時間枠:12 months

To characterize the progression of PNH

12 months
average number of units of packed RBCs transfused per month, of all patients
時間枠:12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with renal failure within follow-up
時間枠:12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with pulmonary hypertension within follow-up
時間枠:12 months

To characterize the progression of PNH

12 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Number and percentage of patients with each symptom of interest within follow-up
時間枠:12 months

To describe clinical characteristics of patients with PNH in China

12 months
Demographics at baseline of all patients
時間枠:baseline

To describe clinical characteristics of patients with PNH in China

baseline
Number and percentage of patients receiving each type of treatment method at baseline and each visit within follow up, including glucocorticoid, red blood cell transfusion, other supportive treatment, bone marrow transplant, eculizumab, of all patients
時間枠:12 months

To describe the treatment pattern of PNH in China

12 months
All serious adverse events (SAEs)of PNH among eculizumab-treated patients
時間枠:12 months

To describe the safety of Eculizumab treatment via Serious Adverse Events

12 months
Standard descriptive statistics of pregnancy status
時間枠:12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of lactation status
時間枠:12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of PNH classification
時間枠:12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of flow cytometry results
時間枠:12 months

To describe clinical characteristics of patients with PNH in China

12 months

その他の成果指標

結果測定
メジャーの説明
時間枠
Concentration of LDH changes at each visit from base-line of PNH among eculizumab-treated patients
時間枠:12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with thrombosis within follow up among eculizumab-treated patients
時間枠:12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
average number of units of packed RBCs transfused per month within 12 months v
時間枠:12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with renal failure within follow up among eculizumab-treated patients
時間枠:12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with pulmonary hypertension (PH) within follow up among eculizumab-treated patients
時間枠:12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

便利なリンク

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年11月10日

一次修了 (実際)

2025年12月3日

研究の完了 (実際)

2025年12月3日

試験登録日

最初に提出

2023年10月30日

QC基準を満たした最初の提出物

2023年11月23日

最初の投稿 (実際)

2023年12月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月24日

QC基準を満たした最後の更新が送信されました

2026年9月22日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • D7414R00001

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD 共有時間枠

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共有アクセス基準

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。